Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Surgery Partners, Inc. (SGRY)

23.24 -0.12 (-0.51%)
At close: October 28 at 4:00:00 PM EDT
23.15 -0.09 (-0.39%)
Pre-Market: 4:03:19 AM EDT
Trade SGRY on Coinbase
Chart Range Bar
Loading chart for SGRY
  • Previous Close 23.36
  • Open 23.26
  • Bid 16.75 x 200
  • Ask 29.83 x 200
  • Day's Range 23.20 - 23.36
  • 52 Week Range 11.41 - 23.44
  • Volume 3,011,521
  • Avg. Volume 3,291,660
  • Market Cap (intraday) 2.995B
  • Beta (5Y Monthly) 1.91
  • PE Ratio (TTM) --
  • EPS (TTM) -0.69
  • Earnings Date Nov 9, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 21.70
  • Zacks Rating Neutral

Surgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery. It offers emergency departments; ancillary services such as physician practices and diagnostic testing; multi-specialty physician practices; urgent care facilities; and anesthesia services. In addition, it offers single- and multi-specialty facilities. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.

www.surgerypartners.com

16,000

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/28/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

SGRY
50.42%
S&P 500 (^GSPC)
13.13%

1-Year Return

SGRY
1.31%
S&P 500 (^GSPC)
12.38%

3-Year Return

SGRY
3.66%
S&P 500 (^GSPC)
88.08%

5-Year Return

SGRY
43.16%
S&P 500 (^GSPC)
68.48%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 848.9M
Earnings -15M
Profit Margin -1.77%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
200M
400M
600M
800M
-4.0%
-3.5%
-3.0%
-2.5%
-2.0%

Analyst Insights

View More

Analyst Price Targets

19.00 Low
21.70 Average
23.24 Current
23.50

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/28/2026
Analyst UBS
Rating Action Downgrade
Rating Neutral
Price Action Raises
Price Target 21 -> 23.5

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -2.63%

  • Return on Assets (ttm)

    3.66%

  • Return on Equity (ttm)

    2.32%

  • Revenue (ttm)

    3.37B

  • Net Income Avi to Common (ttm)

    -88.6M

  • Diluted EPS (ttm)

    -0.69

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    216.7M

  • Total Debt/Equity (mrq)

    117.26%

  • Levered Free Cash Flow (ttm)

    183.56M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: